MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1)

Lin Zhao,Yan Wang,Longyang Jiang,Miao He,Xuefeng Bai,Lifeng Yu,Minjie Wei

DOI: https://doi.org/10.1186/s13046-016-0300-8

2016-02-03

Abstract:Abstract Background The importance of individual microRNAs (miRNAs) in tumor has been established in different cancers. However, their association with tumor chemoresistance has not been fully understood. Previously, we found two novel MDR-associated microRNAs (miRNAs). In this report, we investigated the combined effects of miRNA gene cluster in chemoresistance of breast cancer. Methods This study was performed in two different breast cancer cell lines (MCF-7 and MCF-7/ADR). The levels of miRNAs and mRNA expression were determined by using Quantitative Real-Time PCR. Western blotting was used to detect the levels of protein molecules. Cell viability was assessed by MTS assay. Bioinformatics and Luciferase reporter assay was performed to examine miRNA binding to the 3′-UTR of target genes. Results The miR-302S family including miR-302a, miR-302b, miR-302c, and miR-302d was significantly down-regulated in P-glycoprotein (P-gp)-overexpressing MCF-7/ADR cells. Overexpression of miR-302 increased intracellular accumulation of ADR and sensitized breast cancer cells to ADR. Most importantly, miR-302S produced stronger effects than each individual member alone. The four miRNAs cooperatively downregulate P-gp expression in regulating drug sensitivity. However, our results showed that the suppression of P-gp expression by miR-302 is not through typical miRNA-mediated mRNA degradation but at the level of protein and transcription. Further studies identified MAP/ERK kinase kinase 1 (MEKK1) as a direct and functional target of miR-302. miR-302 showed combinatorial effects on MKEE1 repression and MEKK1-mediated ERK pathway. The suppression of P-gp by miR-302 was reversed by MEKK1 overexpression. Conclusion Our results indicate that miR-302 cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein by targeting MEKK1 of ERK pathway. miR-302 gene cluster may be a potential target for reversing P-gp-mediated chemoresistance in breast cancer.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the resistance of breast cancer cells to the chemotherapeutic drug Adriamycin (ADR). Specifically, the researchers focused on the role of the miR - 302 family (including miR - 302a, miR - 302b, miR - 302c, and miR - 302d) in regulating the sensitivity of breast cancer cells to Adriamycin. The study found that members of the miR - 302 family enhance the sensitivity of breast cancer cells to Adriamycin by down - regulating the expression of P - glycoprotein (P - gp) through targeted inhibition of MAP/ERK kinase kinase 1 (MEKK1). This mechanism may provide a new strategy for reversing the multidrug resistance of breast cancer cells.

The key point of the paper is to reveal how the miR - 302 family works in concert to inhibit the expression of P - gp at the protein and transcriptional levels through an atypical miRNA - mediated mRNA degradation pathway, thereby increasing the sensitivity of breast cancer cells to Adriamycin. In addition, the study also shows that MEKK1, as a direct functional target of miR - 302, its over - expression can reverse the inhibitory effect of miR - 302 on P - gp, further validating the mechanism by which miR - 302 regulates the ERK signaling pathway through MEKK1 to affect P - gp expression.